Listed

Estrella Immunopharma, Inc.

ESLANasdaqCIK 1844417HealthcareFiscal year ends Dec 31

Revenue is not reported in this company’s XBRL financial statements.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenuenot reported (Revenue not reported)No year-earlier figure to compare
  • Gross marginnot reported (Gross profit and Revenue not reported)No year-earlier figure to compare
  • Operating marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Net marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Diluted EPS−$0.05Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001213900-26-089215.Report this figure+66.7% on a year earlier
  • Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare

Last eight quarters

Full statements
Diluted EPS−$0.05, Q2 FY2026
Estrella Immunopharma, Inc., key figures for the last eight quarters
Line itemUnitQ1 FY20252024-09-30Q2 FY20252024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Gross margin%not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)
Operating margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Net margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Diluted EPS$ per share(0.09)Diluted EPS, Q1 FY2025, three months to 2024-09-30−$0.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001213900-25-109198.Report this figurenot reported (Diluted EPS not reported)(0.06)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.06 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-18, accession 0001213900-26-058063.Report this figure(0.15)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001213900-26-089215.Report this figure(0.13)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001213900-25-109198.Report this figurenot reported (Diluted EPS not reported)(0.05)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-18, accession 0001213900-26-058063.Report this figure(0.05)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-13, accession 0001213900-26-089215.Report this figure
Free cash flow$not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Diluted EPS−$0.35, FY2025
Estrella Immunopharma, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-06-30FY20242024-06-30FY20252025-12-31Shape over the periods
Revenue$not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Gross margin%not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)
Operating margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Net margin%not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Diluted EPS$ per sharenot reported (Diluted EPS not reported)not reported (Diluted EPS not reported)(36.35)Diluted EPS, FY2023, twelve months to 2023-06-30−$36.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-09-27, accession 0001213900-24-082374.Report this figure(0.27)Diluted EPS, FY2024, twelve months to 2024-06-30−$0.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-KT filed 2025-03-25, accession 0001013762-25-002190.Report this figure(0.35)Diluted EPS, FY2025, twelve months to 2025-12-31−$0.35 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-18, accession 0001213900-26-029357.Report this figure
Free cash flow$not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Dec 2024 to Nov 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Estrella Immunopharma, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
ARMISTICE CAPITAL, LLC2026-06-30$4.1m3,975,220Reduced−123,780
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$433.5k416,852Added+34,383
BOOTHBAY FUND MANAGEMENT, LLC2026-06-30$197.5k189,899Unchanged
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$147.0k141,321Reduced−16,164
VANGUARD FIDUCIARY TRUST CO2026-06-30$67.5k64,921Unchanged
BlackRock, Inc.2026-06-30$54.1k52,033Added+12,143
STATE STREET CORP2026-06-30$45.0k43,252Unchanged
RENAISSANCE TECHNOLOGIES LLC2026-06-30$40.7k39,100Reduced−23,695
NORTHERN TRUST CORP2026-06-30$36.3k34,861Added+15,237
US BANCORP \DE\2026-06-30$20.8k20,000Added+3,096

Recent filings

All 256 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Estrella Immunopharma, Inc., recent filings
FiledFormWhat it isAccession number
2026-10-2917:28 ET8-K5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits0001213900-26-113912
2026-09-0817:25 ET8-K3.01 Delisting notice0001213900-26-098123
2026-08-2117:00 ET8-K3.01 Delisting notice0001213900-26-092657
2026-08-1317:01 ET10-QQuarterly reportPeriod 2026-06-300001213900-26-089215
2026-06-3017:29 ET8-K5.07 Shareholder vote results0001213900-26-073847
2026-05-2717:25 ETDEF 14AProxy statementPeriod 2026-06-290001140361-26-023012
2026-05-1821:26 ET10-QQuarterly reportPeriod 2026-03-310001213900-26-058063
2026-04-3017:27 ET10-K/AAnnual report, amendedPeriod 2025-12-310001213900-26-050433
2026-03-1820:53 ET10-KAnnual reportPeriod 2025-12-310001213900-26-029357
2026-01-2220:51 ETS-1/ARegistration statement, amended0001213900-26-006410

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 18, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
1844417
Tickers
ESLA, ESLAW
Exchange
Nasdaq
SIC code
2836 Biological Products, (No Diagnostic Substances)
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
not reported
Filer category
<br>Emerging growth company
Former names
TradeUP Acquisition Corp. (to 2023-09-20)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 17:29 ET. Listed shows no prices and gives no investment advice.